Literature DB >> 28289059

What Is Wrong with Pertussis Vaccine Immunity? Why Immunological Memory to Pertussis Is Failing.

Dimitri A Diavatopoulos1, Kathryn Margaret Edwards2,3.   

Abstract

Memory responses seen after whole-cell pertussis (wP) and acellular pertussis (aP) vaccine priming are different and reflect better long-term protection against pertussis disease seen with the whole-cell vaccines. Although acellular vaccines generate higher levels of antigen-specific IgG to the antigens included in the aP vaccines, there are many more pertussis antigens included in whole-cell vaccines. Acellular vaccine priming is associated with skewing of the immune response to a more Th2-like response, whereas whole-cell priming is associated with a Th1/Th17 response. Repeated booster doses of acellular vaccine in children primed with acellular vaccine has been shown to result in progressively shorter duration of protection against disease. This may be explained by the generation of higher levels of antigen-specific IgG4, which does not bind complement and leads to a suboptimal inflammatory response and impaired phagocytosis and antimicrobial defense. In contrast, whole-cell priming followed by aP vaccine boosters results in better opsonization, phagocytosis, and complement mediated killing through the preferential induction of IgG1.
Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28289059      PMCID: PMC5710107          DOI: 10.1101/cshperspect.a029553

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  53 in total

1.  Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines.

Authors:  C M Ausiello; R Lande; F Urbani; A la Sala; P Stefanelli; S Salmaso; P Mastrantonio; A Cassone
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

2.  Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity.

Authors:  James N Francis; Louisa K James; Giannis Paraskevopoulos; Cheukyee Wong; Moises A Calderon; Stephen R Durham; Stephen J Till
Journal:  J Allergy Clin Immunol       Date:  2008-04-18       Impact factor: 10.793

3.  Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children.

Authors:  M Ryan; G Murphy; E Ryan; L Nilsson; F Shackley; L Gothefors; K Oymar; E Miller; J Storsaeter; K H Mills
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

4.  Modulation of the CD4(+) T cell response after acellular pertussis vaccination in the presence of TLR4 ligation.

Authors:  Jolanda Brummelman; Kina Helm; Hendrik-Jan Hamstra; Peter van der Ley; Claire J P Boog; Wanda G H Han; Cécile A C M van Els
Journal:  Vaccine       Date:  2015-02-07       Impact factor: 3.641

5.  Waning immunity to pertussis following 5 doses of DTaP.

Authors:  Sara Y Tartof; Melissa Lewis; Cynthia Kenyon; Karen White; Andrew Osborn; Juventila Liko; Elizabeth Zell; Stacey Martin; Nancy E Messonnier; Thomas A Clark; Tami H Skoff
Journal:  Pediatrics       Date:  2013-03-11       Impact factor: 7.124

6.  Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012.

Authors:  A Zeddeman; M van Gent; C J Heuvelman; H G van der Heide; M J Bart; A Advani; H O Hallander; C H Wirsing von Konig; M Riffelman; J Storsaeter; D F Vestrheim; T Dalby; K A Krogfelt; N K Fry; A M Barkoff; J Mertsola; Q He; F Mooi
Journal:  Euro Surveill       Date:  2014-08-21

7.  Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines.

Authors:  Françoise Vermeulen; Virginie Verscheure; Eliane Damis; Danièle Vermeylen; Gaëlle Leloux; Violette Dirix; Camille Locht; Françoise Mascart
Journal:  Clin Vaccine Immunol       Date:  2009-12-16

8.  Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort.

Authors:  Maxwell A Witt; Larry Arias; Paul H Katz; Elizabeth T Truong; David J Witt
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

9.  Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine.

Authors:  Pádraig J Ross; Caroline E Sutton; Sarah Higgins; Aideen C Allen; Kevin Walsh; Alicja Misiak; Ed C Lavelle; Rachel M McLoughlin; Kingston H G Mills
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

10.  Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.

Authors:  C I Bindon; G Hale; M Brüggemann; H Waldmann
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

View more
  18 in total

1.  Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters.

Authors:  Ricardo da Silva Antunes; Mariana Babor; Chelsea Carpenter; Natalie Khalil; Mario Cortese; Alexander J Mentzer; Grégory Seumois; Christopher D Petro; Lisa A Purcell; Pandurangan Vijayanand; Shane Crotty; Bali Pulendran; Bjoern Peters; Alessandro Sette
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

2.  STING pathway stimulation results in a differentially activated innate immune phenotype associated with low nitric oxide and enhanced antibody titers in young and aged mice.

Authors:  Ross J Darling; Sujata Senapati; Sean M Kelly; Marian L Kohut; Balaji Narasimhan; Michael J Wannemuehler
Journal:  Vaccine       Date:  2019-04-12       Impact factor: 3.641

Review 3.  No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.

Authors:  Thomas C Mitchell; Carolyn R Casella
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

4.  Bordetella pertussis isolates vary in their interactions with human complement components.

Authors:  Charlotte Brookes; Irene Freire-Martin; Breeze Cavell; Frances Alexander; Stephen Taylor; Ruby Persaud; Norman Fry; Andrew Preston; Dimitri Diavatopoulos; Andrew Gorringe
Journal:  Emerg Microbes Infect       Date:  2018-05-09       Impact factor: 7.163

Review 5.  First International Precision Vaccines Conference: Multidisciplinary Approaches to Next-Generation Vaccines.

Authors:  Francesco Borriello; Simon D van Haren; Ofer Levy
Journal:  mSphere       Date:  2018-08-01       Impact factor: 4.389

Review 6.  A Review on T Cell Epitopes Identified Using Prediction and Cell-Mediated Immune Models for Mycobacterium tuberculosis and Bordetella pertussis.

Authors:  Yuan Tian; Ricardo da Silva Antunes; John Sidney; Cecilia S Lindestam Arlehamn; Alba Grifoni; Sandeep Kumar Dhanda; Sinu Paul; Bjoern Peters; Daniela Weiskopf; Alessandro Sette
Journal:  Front Immunol       Date:  2018-11-29       Impact factor: 7.561

7.  Lack of evidence supporting a role of IFN-β and TGF-β in differential polarization of Bordetella pertussis specific-T cell responses.

Authors:  Ricardo da Silva Antunes; Lorenzo G Quiambao; Ferran Soldevila; Aaron Sutherland; Bjoern Peters; Alessandro Sette
Journal:  Cytokine       Date:  2020-09-29       Impact factor: 3.861

8.  A system-view of Bordetella pertussis booster vaccine responses in adults primed with whole-cell versus acellular vaccine in infancy.

Authors:  Ricardo da Silva Antunes; Ferran Soldevila; Mikhail Pomaznoy; Mariana Babor; Jason Bennett; Yuan Tian; Natalie Khalil; Yu Qian; Aishwarya Mandava; Richard H Scheuermann; Mario Cortese; Bali Pulendran; Christopher D Petro; Adrienne P Gilkes; Lisa A Purcell; Alessandro Sette; Bjoern Peters
Journal:  JCI Insight       Date:  2021-04-08

9.  Protection against Pertussis in Humans Correlates to Elevated Serum Antibodies and Memory B Cells.

Authors:  Valentina Marcellini; Eva Piano Mortari; Giorgio Fedele; Francesco Gesualdo; Elisabetta Pandolfi; Fabio Midulla; Pasqualina Leone; Paola Stefanelli; Alberto Eugenio Tozzi; Rita Carsetti
Journal:  Front Immunol       Date:  2017-09-15       Impact factor: 7.561

10.  Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose.

Authors:  Megan Laudenbach; Federico Baruffaldi; Christine Robinson; Philipp Carter; Davis Seelig; Carly Baehr; Marco Pravetoni
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.